Publications by authors named "Andreas Diacon"

Claim this Profile

Mentions over time

Mentions by platform

Video Views

421,409

Total Likes

967

Extended Reach

856,526

Social Features

112
F
Final Analysis of a Trial of M72/AS01 Vaccine to Prevent Tuberculosis.
Dereck R Tait, Mark Hatherill, Olivier Van Der Meeren, Ann M Ginsberg, Elana Van Brakel, Bruno Salaun, Thomas J Scriba, Elaine J Akite, Helen M Ayles, Anne Bollaerts

N Engl J Med· December 2019

Videos about Article: user user

2 21 110 6 86

View All Article and Social Media Activity
C
Clinical testing of drug treatment shortening in patients with TB using PET/CT imaging of lung lesions.
Stephanus T Malherbe, Ray Y Chen, Xiang Yu, Bronwyn Smith, Xin Liu, Andreas H Diacon

Sci Transl Med· January 2026

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase 2a Study of the Early Bactericidal Activity of Rifampicin in Combination With Meropenem Plus Amoxicillin/Clavulanate Among Adults With Rifampicin-Resistant Pulmonary Tuberculosis.
Veronique de Jager, Laurynas Mockeliunas, Huifang You, Ulrika S H Simonsson, Tarryn Collings, Andreas H Diacon

Clin Infect Dis· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bridging to Paediatric Dosing: Relative Bioavailability of Suspended Rifapentine and Isoniazid in an Open-Label Randomized Trial in Adults on Tuberculosis Preventive Therapy.
Saskia Janssen, Thanakorn Vongjarudech, Mats O Karlsson, Caryn M Upton, Anthony J Garcia-Prats, Andreas H Diacon

Clin Pharmacokinet· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cerebrospinal fluid penetration of cycloserine/terizidone and clofazimine in patients with pulmonary TB.
Caryn M Upton, Jose M Calderin, Andreas H Diacon, Martin J Boeree, Paolo Denti

Antimicrob Agents Chemother· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neutralizing and binding antibodies are a correlate of risk of COVID-19 in the CoVPN 3008 study in people with HIV.
Nonhlanhla N Mkhize, Bo Zhang, Caroline Brackett, Peter James Elyanu, Asa Tapley, Andreas Henri Diacon

Nat Commun· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Telacebec, a Potent Agent in the Fight against Tuberculosis: Findings from a Randomized, Phase 2 Clinical Trial and Beyond.
Saskia Janssen, Caryn Upton, Veronique R de Jager, Christo van Niekerk, Rodney Dawson, Andreas H Diacon

Am J Respir Crit Care Med· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunogenicity, safety, and efficacy of the vaccine H56:IC31 in reducing the rate of tuberculosis disease recurrence in HIV-negative adults successfully treated for drug-susceptible pulmonary tuberculosis: a double-blind, randomised, placebo-controlled, phase 2b trial.
Álvaro H Borges, Marisa Russell, Dereck Tait, Thomas J Scriba, Elisa Nemes, Andreas H Diacon

Lancet Infect Dis· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Safety of Higher Doses of Levofloxacin for Multidrug-resistant Tuberculosis: A Randomized, Placebo-controlled Phase II Clinical Trial.
Patrick P J Phillips, Charles A Peloquin, Timothy R Sterling, Pawandeep Kaur, Andreas H Diacon

Am J Respir Crit Care Med· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Population pharmacokinetics and exposure-response relationship of the antituberculosis drug BTZ-043.
Simon E Koele, Norbert Heinrich, Veronique R De Jager, Julia Dreisbach, Patrick P J Phillips, Andreas H Diacon

J Antimicrob Chemother· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Author Correction: Risk-stratified treatment for drug-susceptible pulmonary tuberculosis.
Vincent K Chang, Marjorie Z Imperial, Patrick P J Phillips, Gustavo E Velásquez, Payam Nahid, Andreas H Diacon

Nat Commun· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
Quantification of bactericidal activity using the PATHFAST TB LAM Ag assay during the first 14 days of pulmonary tuberculosis treatment.
Ayumi Akinaga, Andreas H Diacon, Remous Ocloo, Atsushi Yanagida, Naofumi Yoda

Front Antibiot· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety, pharmacokinetics, and early bactericidal activity of quabodepistat in combination with delamanid, bedaquiline, or both in adults with pulmonary tuberculosis: a randomised, active-controlled, open-label trial.
Rodney Dawson, Andreas H Diacon, Veronique De Jager, Kim Narunsky, V Mischka Moodley

Lancet Infect Dis· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tuberculosis: An Update for the Clinician.
Saskia Janssen, Melissa Murphy, Caryn Upton, Brian Allwood, Andreas H Diacon

Respirology· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety, bactericidal activity, and pharmacokinetics of the antituberculosis drug candidate BTZ-043 in South Africa (PanACEA-BTZ-043-02): an open-label, dose-expansion, randomised, controlled, phase 1b/2a trial.
Norbert Heinrich, Veronique de Jager, Julia Dreisbach, Petra Gross-Demel, Susanne Schultz, Andreas H Diacon

Lancet Microbe· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hybrid versus vaccine immunity of mRNA-1273 among people living with HIV in East and Southern Africa: a prospective cohort analysis from the multicentre CoVPN 3008 (Ubuntu) study.
Nigel Garrett, Asa Tapley, Aaron Hudson, Sufia Dadabhai, Bo Zhang, Andreas Henri Diacon

EClinicalMedicine· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pyrazinamide Safety, Efficacy, and Dosing for Treating Drug-Susceptible Pulmonary Tuberculosis: A Phase 3, Randomized Controlled Clinical Trial.
Ava Y Xu, Gustavo E Velásquez, Nan Zhang, Vincent K Chang, Patrick P J Phillips, Andreas Diacon

Am J Respir Crit Care Med· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety, effectiveness and immunogenicity of heterologous mRNA-1273 boost after prime with Ad26.COV2.S among healthcare workers in South Africa: The single-arm, open-label, phase 3 SHERPA study.
Nigel Garrett, Tarylee Reddy, Nonhlanhla Yende-Zuma, Azwidhwi Takalani, Kubashni Woeber, Andreas H Diacon

PLOS Glob Public Health· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and Immunogenicity of the H56:IC31 Tuberculosis Vaccine Candidate in Adults Successfully Treated for Drug-Susceptible Pulmonary Tuberculosis: A Phase 1 Randomized Trial.
Dereck Tait, Andreas Diacon, Álvaro H Borges, Elana van Brakel, David Hokey

J Infect Dis· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Co-regulation of innate and adaptive immune responses induced by ID93+GLA-SE vaccination in humans.
Andrew Fiore-Gartland, Himangi Srivastava, Aaron Seese, Tracey Day, Adam Penn-Nicholson, Andreas Diacon

Front Immunol· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Risk-stratified treatment for drug-susceptible pulmonary tuberculosis.
Vincent K Chang, Marjorie Z Imperial, Patrick P J Phillips, Gustavo E Velásquez, Payam Nahid, Andreas H Diacon

Nat Commun· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PET/CT guided tuberculosis treatment shortening: a randomized trial.
Stephanus T Malherbe, Ray Y Chen, Xiang Yu, Bronwyn Smith, Xin Liu, Andreas H Diacon

medRxiv· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
High-Dose Isoniazid Lacks EARLY Bactericidal Activity against Isoniazid-resistant Tuberculosis Mediated by katG Mutations: A Randomized Phase II Clinical Trial.
Kamunkhwala Gausi, Elisa H Ignatius, Veronique De Jager, Caryn Upton, Soyeon Kim, Andreas H Diacon

Am J Respir Crit Care Med· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Target regimen profiles for tuberculosis treatment.
Christian Lienhardt, Kelly E Dooley, Payam Nahid, Charles Wells, Theresa S Ryckman, Andreas Diacon

Bull World Health Organ· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A first-in-class leucyl-tRNA synthetase inhibitor, ganfeborole, for rifampicin-susceptible tuberculosis: a phase 2a open-label, randomized trial.
Andreas H Diacon, Clifton E Barry, Alex Carlton, Ray Y Chen, Matt Davies

Nat Med· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Risk Factors for COVID-19 and Respiratory Tract Infections during the Coronavirus Pandemic.
Laurynas Mockeliunas, Rob C van Wijk, Caryn M Upton, Jonathan Peter, Andreas H Diacon

Vaccines (Basel)· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis